Therapeutic Agents for Kidney Repair

Johnson & Johnson Innovation is interested in developing therapeutics for kidney diseases, including Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), Acute Kidney Injury (AKI), Autosomal Dominant Polycystic Kidney Disease (ADPKD), and other selected rare kidney diseases. Johnson & Johnson Innovation is looking for novel compounds, targets or pathways with the objective to repair kidney damage caused by CKD, AKI, or major types of rare kidney diseases.

The primary interest is focused on pharmacological strategies for kidney repair in situ, such as reparative factors with the ability to trigger the kidney to repair itself, including the induction of dedifferentiation of resident renal cells, as well as other approaches.

Modalities of Interest

Johnson & Johnson Innovation is agnostic to modalities, including small molecules, biologics, RNA therapeutics, gene therapy, and will consider any route of administration if it is meaningful for the targeted patient populations.

Stage of Development

Basic research through to clinical phase I stage is of interest. Pre-requisites: Johnson & Johnson Innovation requires good understanding of target biology, with opportunities ideally accompanied by pre-clinical data demonstrating a signal for efficacy e.g. in vitro and/or in vivo models.

Out of Scope

- Repurposed compounds which have been commercialised
- Cell therapy approaches, regardless sources of stem cells
- Bioengineering of kidney ex vivo to replace damaged kidney

Submission Information & Potential Collaborations for Academics

- Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information
- Johnson & Johnson Innovation is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include project/PhD funding and research collaborations